Dapagliflozin attenuates diabetic cardiomyopathy via NRF2 protein upregulation-driven glutathione synthesis to inhibit myocardial ferroptosis. (PubMed, Life Sci) - Jun 24, 2025 - "DAPA attenuates type 2 DCM via NRF2 protein upregulation-driven glutathione synthesis to inhibit myocardial ferroptosis, identifying upregulation of NRF2 as a promising therapeutic target for ferroptosis intervention in type 2 DCM."
Journal • Cardiomyopathy • Cardiovascular • Diabetes • Hematological Disorders • Type 2 Diabetes Mellitus • GPX4 • SLC7A11
|
|
Guoan Wang; Hongyan Dai; Jun Guan; Li Gong; Likun Zhuang; Mengran Wang; Tianying Wang; Xi Liu; Xuepin Chen; Yan Gao
|